HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.

AbstractOBJECTIVES:
Hepatocellular carcinoma (HCC) is a common cancer with high rate of recurrence and mortality. Diverse aetiological agents and wide heterogeneity in individual tumours impede effective and personalised treatment. Tonicity-responsive enhancer-binding protein (TonEBP) is a transcriptional cofactor for the expression of proinflammatory genes. Although inflammation is intimately associated with the pathogenesis of HCC, the role of TonEBP is unknown. We aimed to identify function of TonEBP in HCC.
DESIGN:
Tumours with surrounding hepatic tissues were obtained from 296 patients with HCC who received completion resection. TonEBP expression was analysed by quantitative reverse transcription-quantitative real-time PCR (RT-PCR) and immunohfistochemical analyses of tissue microarrays. Mice with TonEBP haplodeficiency, and hepatocyte-specific and myeloid-specific TonEBP deletion were used along with HCC and hepatocyte cell lines.
RESULTS:
TonEBP expression is higher in tumours than in adjacent non-tumour tissues in 92.6% of patients with HCC regardless of aetiology associated. The TonEBP expression in tumours and adjacent non-tumour tissues predicts recurrence, metastasis and death in multivariate analyses. TonEBP drives the expression of cyclo-oxygenase-2 (COX-2) by stimulating the promoter. In mouse models of HCC, three common sites of TonEBP action in response to diverse aetiological agents leading to tumourigenesis and tumour growth were found: cell injury and inflammation, induction by oxidative stress and stimulation of the COX-2 promoter.
CONCLUSIONS:
TonEBP is a key component of the common pathway in tumourigenesis and tumour progression of HCC in response to diverse aetiological insults. TonEBP is involved in multiple steps along the pathway, rendering it an attractive therapeutic target as well as a prognostic biomarker.
AuthorsJun Ho Lee, Jae Hee Suh, Soo Youn Choi, Hyun Je Kang, Hwan Hee Lee, Byeong Jin Ye, Gap Ryol Lee, Seok Won Jung, Chang Jae Kim, Whaseon Lee-Kwon, Jiyoung Park, Kyungjae Myung, Neung Hwa Park, Hyug Moo Kwon
JournalGut (Gut) Vol. 68 Issue 2 Pg. 347-358 (02 2019) ISSN: 1468-3288 [Electronic] England
PMID29420225 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Chemical References
  • NFAT5 protein, human
  • Nfat5 protein, mouse
  • Transcription Factors
  • Cyclooxygenase 2
Topics
  • Animals
  • Carcinogenesis (metabolism)
  • Carcinoma, Hepatocellular (metabolism)
  • Cyclooxygenase 2 (metabolism)
  • Disease Models, Animal
  • Disease Progression
  • Female
  • Humans
  • Liver Neoplasms (metabolism)
  • Male
  • Mice
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local (metabolism)
  • Oxidative Stress
  • Predictive Value of Tests
  • Republic of Korea
  • Survival Rate
  • Transcription Factors (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: